These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539 [TBL] [Abstract][Full Text] [Related]
5. Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States. Gower EW; Stein JD; Shekhawat NS; Mikkilineni S; Blachley TS; Pajewski NM Am J Ophthalmol; 2017 Dec; 184():157-166. PubMed ID: 29106914 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037 [TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Chong EW; Al-Qureshi SH Clin Exp Ophthalmol; 2017 May; 45(4):333-335. PubMed ID: 28618455 [No Abstract] [Full Text] [Related]
9. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. Brown GC; Brown MM; Rapuano SB; Boyer D Am J Ophthalmol; 2021 Mar; 223():405-429. PubMed ID: 32681907 [TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G; Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns. Phakey S; Hall AJ; Lim LL Ophthalmic Epidemiol; 2024 Feb; 31(1):94-97. PubMed ID: 36794374 [TBL] [Abstract][Full Text] [Related]
12. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973 [TBL] [Abstract][Full Text] [Related]
13. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
14. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958 [TBL] [Abstract][Full Text] [Related]
15. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
16. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. Ziemssen F; Feltgen N; Holz FG; Guthoff R; Ringwald A; Bertelmann T; Wiedon A; Korb C; BMC Ophthalmol; 2017 Jan; 17(1):7. PubMed ID: 28103831 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. Bellerive C; Cinq-Mars B; Lalonde G; Malenfant M; Tourville E; Tardif Y; Giasson M; Hébert M Can J Ophthalmol; 2012 Apr; 47(2):165-9. PubMed ID: 22560423 [TBL] [Abstract][Full Text] [Related]
18. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Berg K; Pedersen TR; Sandvik L; Bragadóttir R Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model. Vottonen P; Kankaanpää E Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]